Skip Navigation



NDT Advance Access published online on March 22, 2006

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl118
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/7/1915    most recent
gfl118v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jung, H. H.
Right arrow Articles by Han, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jung, H. H.
Right arrow Articles by Han, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received January 21, 2006
Accepted February 23, 2006


Original Article

Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis

Hae Hyuk Jung 1 *, Sang-Wook Kim 1, and Heon Han 2

1 Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chunchon, Kangwon-do, Republic of Korea
2 Department of Radiology, Kangwon National University Hospital, Kangwon National University School of Medicine, Chunchon, Kangwon-do, Republic of Korea

* To whom correspondence should be addressed.
Hae Hyuk Jung, E-mail: haehyuk{at}kangwon.ac.kr



  Abstract

Background. Coronary artery calcification (CAC) is an extensive and common complication in patients with end-stage renal disease (ESRD). The aim of this study was to assess prospectively the change in CAC over a 2-year period and to identify the factors that may be associated with CAC progression in ESRD patients.

Methods. The final analysis was performed on 40 of 43 stable haemodialysis patients who initially entered into the study. The study population underwent multirow spiral computed tomography to derive CAC scores at baseline and after a minimum of 12 months (24 months in 30 patients, 18 months in four, and 12 months in the remaining six patients). To provide a stable estimate that was unbiased with respect to the baseline CAC, square root-transformed CAC scores were used for the analyses of the changes in CAC.

Results. The median CAC score was 191 (range, 0-2403) mm3 at baseline and increased to 253 (range, 0-2745) mm3 at follow-up (P<0.001) and the median annualized change in square root-transformed CAC score was 1.48 (range, -0.95-8.64) mm3/year. The annualized change of the square root-transformed CAC score positively correlated with the time-integrated levels of C-reactive protein (R = 0.521, P = 0.001), phosphorus (R = 0.433, P = 0.005) and calcium x phosphorus product (R = 0.394, P = 0.012), but did not correlate with the levels of fetuin-A or lipid parameters. Even after adjusting for age, gender and baseline CAC score, C-reactive protein levels were independently associated with CAC progression.

Conclusion. These data suggest that chronic inflammation as well as altered mineral metabolism contributes to a rapid progression of CAC in ESRD patients. Additional, larger scale studies are required to confirm our findings.

Keywords: coronary artery calcification; C-reactive protein; end-stage renal disease; fetuin-A; mineral metabolism.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CJASNHome page
J. F. Navarro-Gonzalez, C. Mora-Fernandez, M. Muros, H. Herrera, and J. Garcia
Mineral Metabolism and Inflammation in Chronic Kidney Disease Patients: A Cross-Sectional Study
Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1646 - 1654.
[Abstract] [Full Text] [PDF]


Home page
pdiHome page
A. Y.-M. Wang
VASCULAR AND OTHER TISSUE CALCIFICATION IN PERITONEAL DIALYSIS PATIENTS
Perit. Dial. Int., February 1, 2009; 29(Supplement_2): S9 - S14.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
G. Saab, A. T. Whaley-Connell, R. Khanna, and J. R. Sowers
Review: Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification
Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 107 - 112.
[Abstract] [PDF]


Home page
DiabetesHome page
D. M. Maahs, L. G. Ogden, A. Kretowski, J. K. Snell-Bergeon, G. L. Kinney, T. Berl, and M. Rewers
Serum Cystatin C Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals With Type 1 Diabetes
Diabetes, November 1, 2007; 56(11): 2774 - 2779.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Boehme, F. Kaehne, A. Kuehne, W. Bernhardt, M. Schroder, W. Pommer, C. Fischer, H. Becker, C. Muller, and R. Schindler
Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2224 - 2229.
[Abstract] [Full Text] [PDF]


Home page
pdiHome page
A. Y.-M. Wang
CARDIOVASCULAR RISK FACTORS IN PERITONEAL DIALYSIS PATIENTS REVISITED
Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S223 - S227.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. Fournier, L. Harbouche, J. Mansour, and I. Shahapuni
Impact of calcium and vitamin D therapy on arterial and cardiac disease in young adults with childhood-onset end stage renal disease
Nephrol. Dial. Transplant., March 1, 2007; 22(3): 956 - 957.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.